Related Experiment Video
Updated: Aug 14, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current
Anna Klimczak1, Katarzyna Kisielewska2, Anna Szumera-Ciećkiewicz3
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Ul. Roentgena 5, 02-781, Warsaw, Poland.
Abstract:
Gastrointestinal stromal tumors are the most common sarcomas of the gastrointestinal tract. They are characterized by a distinct molecular profile, most frequently involving activating mutations in the KIT or PDGFRA genes, the identification of which has enabled the development of effective targeted therapies and has significantly improved patient outcomes. Despite significant therapeutic advances, treatment with tyrosine kinase inhibitors remains associated with the risk of primary or secondary resistance in a subset of patients. This phenomenon has highlighted the considerable biological heterogeneity of gastrointestinal stromal tumor, encompassing not only canonical mutational variants but also rare molecular alterations with distinct pathogenic mechanisms and clinical implications. Growing evidence suggests that detailed molecular characterization of gastrointestinal stromal tumors is of critical clinical importance, enabling improved risk stratification, optimization of treatment selection, and identification of patients requiring alternative therapeutic strategies. Therefore, comprehensive molecular diagnostics should be an integral part of the diagnostic and therapeutic approach to this heterogeneous group of tumors. The aim of this study is to provide an overview of current knowledge on rare molecular variants of gastrointestinal stromal tumors, as well as the available data on their clinical course and sensitivity to tyrosine kinase inhibitors and other therapeutic strategies.
Insights
Gastrointestinal stromal tumors (GISTs) show significant molecular diversity beyond common KIT/PDGFRA mutations. Understanding rare variants is crucial for personalized treatment and overcoming tyrosine kinase inhibitor resistance.
Area of Science:
- Oncology
- Molecular Pathology
- Gastrointestinal Oncology
Background:
- Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal sarcomas.
- Activating mutations in KIT or PDGFRA genes are frequent, driving targeted therapy development.
- Primary and secondary resistance to tyrosine kinase inhibitors (TKIs) remain significant clinical challenges.
Purpose of the Study:
- To provide an overview of rare molecular variants in GISTs.
- To summarize clinical courses and therapeutic sensitivities associated with these rare variants.
- To emphasize the importance of comprehensive molecular diagnostics in GIST management.
Main Methods:
- Review of current literature on GIST molecular heterogeneity.
- Analysis of data on rare molecular alterations, their pathogenic mechanisms, and clinical implications.
- Evaluation of sensitivity to TKIs and alternative therapeutic strategies for rare GIST variants.
Main Results:
- GISTs exhibit considerable biological heterogeneity beyond canonical mutations.
- Rare molecular alterations have distinct pathogenic mechanisms and clinical implications.
- Detailed molecular characterization aids in risk stratification and treatment selection.
Conclusions:
- Comprehensive molecular diagnostics are essential for optimal GIST patient management.
- Understanding rare variants is critical for improving treatment strategies and patient outcomes.
- Further research into rare GIST molecular alterations is warranted.
